Clinical Trials Browser

OTHER × Carcinoma, Non-Small-Cell Lung × disitamab vedotin × Clear all

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung